Identification and validation of a novel long non-coding RNA (LINC01465) in ovarian cancer

[1]  K. Gomes,et al.  Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells , 2022, Non-coding RNA.

[2]  Jianghu Huang,et al.  LINC00662 facilitates osteosarcoma progression via sponging miR‐103a‐3p and regulating SIK2 expression , 2021, Journal of tissue engineering and regenerative medicine.

[3]  B. Zhivotovsky,et al.  Long non-coding RNAs: A view to kill ovarian cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[4]  B. Tsang,et al.  Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis , 2021, Molecules.

[5]  W. Wang,et al.  Long Non-Coding RNA LINC00313 Accelerates Cervical Carcinoma Progression by miR-4677-3p/CDK6 Axis , 2021, OncoTargets and therapy.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  Yuqin Wang,et al.  LncRNA MALAT1 Regulates the Progression and Cisplatin Resistance of Ovarian Cancer Cells via Modulating miR-1271-5p/E2F5 Axis , 2020, Cancer management and research.

[8]  H. You,et al.  LncRNA SOCS2-AS1 inhibits progression and metastasis of colorectal cancer through stabilizing SOCS2 and sponging miR-1264 , 2020, Aging.

[9]  A. Okamoto,et al.  FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β-catenin activity in ovarian cancer , 2020, BMC Cancer.

[10]  Lei Wang,et al.  lncRNA MEG3 modified epithelial‐mesenchymal transition of ovarian cancer cells by sponging miR‐219a‐5p and regulating EGFR , 2019, Journal of cellular biochemistry.

[11]  Enxin Zhang,et al.  Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue , 2019, BMC Cancer.

[12]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[13]  Chen Yu,et al.  Long noncoding RNA SNHG6 functions as a competing endogenous RNA by sponging miR-181a-5p to regulate E2F5 expression in colorectal cancer , 2019, Cancer management and research.

[14]  Anushya Muruganujan,et al.  PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools , 2018, Nucleic Acids Res..

[15]  Jia Hu,et al.  The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1 , 2018, Journal of experimental & clinical cancer research : CR.

[16]  J. Peters,et al.  Molecular Regulation of Carcinogenesis: Friend and Foe. , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[18]  Qian Xu,et al.  A comprehensive evaluation for polymorphisms in let-7 family in cancer risk and prognosis: a system review and meta-analysis , 2018, Bioscience reports.

[19]  F. Dick,et al.  Structural Conservation and E2F Binding Specificity within the Retinoblastoma Pocket Protein Family. , 2016, Journal of molecular biology.

[20]  H. Tian,et al.  miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. , 2016, American journal of translational research.

[21]  Yanqing Ding,et al.  MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. , 2015, Experimental and molecular pathology.

[22]  Hua Tang,et al.  Up-regulated MicroRNA-181a induces carcinogenesis in Hepatitis B virus-related hepatocellular carcinoma by targeting E2F5 , 2014, BMC Cancer.

[23]  D. Ichikawa,et al.  E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma. , 2013, Anticancer research.

[24]  S. Shah,et al.  Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research , 2013, PloS one.

[25]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[26]  Xin Fu,et al.  Analysis of genetic aberrations on chromosomal region 8q21–24 identifies E2F5 as an oncogene with copy number gain in prostate cancer , 2013, Medical Oncology.

[27]  A. Morillon,et al.  Noncoding RNAs in gene regulation , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[28]  Bei Zhang,et al.  An overview of biomarkers for the ovarian cancer diagnosis. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[29]  A. Chinnaiyan,et al.  The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.

[30]  Howard Y. Chang,et al.  Molecular mechanisms of long noncoding RNAs. , 2011, Molecular cell.

[31]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[32]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[33]  Vladimir B Bajic,et al.  E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer , 2010, BMC Cancer.

[34]  J. Mattick,et al.  Long non-coding RNAs: insights into functions , 2009, Nature Reviews Genetics.

[35]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[36]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[37]  T. Volkert,et al.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. , 2002, Genes & development.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  G. Mills,et al.  Genetic analysis of early- versus late-stage ovarian tumors. , 2001, Cancer research.

[40]  J. Nevins,et al.  E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. , 2000, Molecular cell.

[41]  E. Miyagi,et al.  Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. , 1995, Gynecologic oncology.

[42]  Kai Huang,et al.  Non-coding RNAs as regulators in epigenetics (Review). , 2017, Oncology reports.

[43]  Chandrasekhar Kanduri,et al.  Long Noncoding RNA: Genome Organization and Mechanism of Action. , 2017, Advances in experimental medicine and biology.

[44]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .